1. Pabla N and Dong Z: Cisplatin nephrotoxicity: Mechanisms and
renoprotective strategies. Kidney Int 73: 994‑1007, 2008.
2. Perazella MA and Moeckel GW: Nephrotoxicity from chemo‑
therapeutic agents: Clinical manifestations, pathobiology and
prevention/therapy. Semin Nephrol 30: 570‑581, 2010.
3. Didier Portilla, A Mazin Safar and Melissa L Shannon: Cisplatin
nephrotoxicity. Post TW, ed. UpToDate. Waltham, MA:
UptoDate Inc. https://www.uptodate.com/contents/cisplatinnephrotoxicity. Accessed February 26, 2019.
4. Dobyan DC, Levi J, Jacobs C, Kosek J and Weiner MW:
Mechanism of cis‑platinum nephrotoxicity: II. Morphologic
observations. J Pharmacol Exp Ther 213: 551‑556, 1980.
5. Sobrero A, Guglielmi A, Aschele C and Rosso R: Current strate‑
gies to reduce cisplatin toxicity. J Chemother 2: 3‑7, 1990.
6. de Jongh FE, van Veen RN, Veltman SJ, de Wit R,
van der Burg ME, van den Bent MJ, Planting AS, Graveland WJ,
Stoter G and Verweij J: Weekly high‑dose cisplatin is a feasible
treatment option: Analysis on prognostic factors for toxicity in
400 patients. Br J Cancer 88: 1199‑1206, 2003.
7. Hinai Y, Motoyama S, Niioka T and Miura M: Absence of effect
of SLC22A2 genotype on cisplatin‑induced nephrotoxicity in
oesophageal cancer patients receiving cisplatin and 5‑fluoro‑
uracil: Report of results discordant with those of earlier studies.
J Clin Pharm Ther 38: 498‑503, 2013.
8. Zhang J and Zhou W: Ameliorative effects of SLC22A2 gene
polymorphism 808 G/T and cimetidine on cisplatin‑induced
nephrotoxicity in Chinese cancer patients. Food Chem
Toxicol 50: 2289‑2293, 2012.
9. Iwata K, Aizawa K, Kamitsu S, Jingami S, Fukunaga E,
Yoshida M, Yoshimura M, Hamada A and Saito H: Effects
of genetic variants in SLC22A2 organic cation transporter 2
and SLC47A1 multidrug and toxin extrusion 1 transporter on
cisplatin‑induced adverse events. Clin Exp Nephrol 16: 843‑851,
2012.
10. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH and
Sparreboom A: Contribution of organic cation transporter 2
(OCT2) to cisplatin‑induced nephrotoxicity. Clin Pharmacol
Ther 86: 396‑402, 2009.
11. Tzvetkov MV, Behrens G, O'Brien VP, Hohloch K, Brockmöller J
and Benöhr P: Pharmacogenetic analyses of cisplatin‑induced
nephrotoxicity indicate a renoprotective effect of ERCC1 poly‑
morphisms. Pharmacogenomics 12: 1417‑1427, 2011.
12. Windsor RE, Strauss SJ, Kallis C, Wood NE and Whelan JS:
Germline genetic polymorphisms may influence chemotherapy
response and disease outcome in osteosarcoma: A pilot study.
Cancer 118, 1856‑1867, 2012.
13. Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C,
Bowles DW, George B, Wen X, Aleksunes LM and Joy MS:
Pharmacogenomic variants may influence the urinary excretion
of novel kidney injury biomarkers in patients receiving cisplatin.
Int J Mol Sci 18: 1333, 2017.
14. Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, Veltman J,
Baas P, Masereeuw R and Maitland‑van der Zee AH: Genetic
variations and cisplatin nephrotoxicity: A systematic review.
Front Pharmacol 9: 1111, 2018.
15. Pavlidis P and Nobel WS: Analysis of strain and regional
variation in gene expression in mouse brain. Genome Biol 2:
Research0042, 2001.
16. Howe EA, Sinha R, Schlauch D and Quackenbush J: RNA‑Seq
analysis in MeV. Bioinformatics 27: 3209‑3210, 2011.
17. Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY,
Clark‑Snow R A, Danso MA, Dennis K, Dupuis LL,
Dusetzina SB, et al: Antiemetics: American society of clinical
oncology clinical practice guideline update. J Clin Oncol 35:
3240‑3261, 2017.
18. Dilruba S and Kalayda GV: Platinum‑based drugs: Past, present
and future. Cancer Chemother Pharmacol 77: 1103‑1124, 2016.
19. Innocenti F, Schilsky RL, Ramírez J, Janisch L, Undevia S,
House LK, Das S, Wu K, Turcich M, Marsh R, et al: Dose-finding
and pharmacokinetic study to optimize the dosing of irinotecan
according to the UGT1A1 genotype of patients with cancer.
J Clin Oncol 32: 2328‑2334, 2014.
20. Henricks LM, Opdam FL, Beijnen JH, Cats A and Schellens JHM:
DPYD genotype-guided dose individualization to improve
patient safety of fluoropyrimidine therapy: Call for a drug label
update. Ann Oncol 28: 2915‑2922, 2017.
21. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui
CH, Yee SW, Stein CM, Carrillo M, Evans WE and Klein TE;
Clinical Pharmacogenetics Implementation Consortium: Clinical
pharmacogenetics implementation consortium guidelines for
thiopurine methyltransferase genotype and thiopurine dosing.
Clin Pharmacol Ther 89: 387‑391, 2011.
This work is licensed under a Creative Commons
Attribution-NonCommercial-NoDerivatives 4.0
International (CC BY-NC-ND 4.0) License.
...
論文の公開元へ
